Potential role of immunotherapy in advanced non-small-cell lung cancer

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• ThomasAGiacconeGWhy has active immunotherapy not worked in lung cancer?Ann Oncol201526112213222026232492
   PubMed Web of Science ®Google Scholar
• La-BeckNMJeanGWHuynhCAlzghariSKLoweDBImmune checkpoint inhibitors: new insights and current place in cancer therapyPharmacotherapy2015351096397626497482
   PubMed Web of Science ®Google Scholar
• AdaGThe coming of age of tumour immunotherapyImmunol Cell Biol199977218018510234555
   PubMedGoogle Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• ReimanJMKmieciakMManjiliMHKnutsonKLTumor immunoediting and immunosculpting pathways to cancer progressionSemin Cancer Biol200717427528717662614
   PubMed Web of Science ®Google Scholar
• SmythMJThiaKYStreetSEMacGregorDGodfreyDITrapaniJAPerforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphomaJ Exp Med2000192575576010974040
   PubMed Web of Science ®Google Scholar
• PageDBBourlaABDaniyanATumor immunology and cancer immunotherapy: summary of the 2014 SITC primerJ Immunother Cancer20153125
   Google Scholar
• SchreiberRDOldLJSmythMJCancer immunoediting: integrating immunity’s roles in cancer suppression and promotionScience201133160241565157021436444
   PubMed Web of Science ®Google Scholar
• GiacconeGBazhenovaLANemunaitisJA phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancerEur J Cancer2321511623212329
   Google Scholar
• ButtsCSocinskiMAMitchellPLTecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialLancet Oncol2014151596824331154
   PubMed Web of Science ®Google Scholar
• RibasAReleasing the brakes on cancer immunotherapyN Engl J Med2015373161490149226348216
   PubMed Web of Science ®Google Scholar
• AguiarPNJrSantoroILTadokoroHA pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarkerImmunotherapy2016891011101927485075
   PubMed Web of Science ®Google Scholar
• MadureiraPde MelloRAde VasconcelosAZhangYImmunotherapy for lung cancer: for whom the bell tolls?Tumor Biol201536314111422
   PubMedGoogle Scholar
• ErnstBAndersonKSImmunotherapy for the treatment of breast cancerCurr Oncol Rep2015172525677118
   PubMedGoogle Scholar
• ShankaranVIkedaHBruceATIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature200141068321107111111323675
   PubMed Web of Science ®Google Scholar
• DigheASRichardsEOldLJSchreiberRDEnhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptorsImmunity1994164474567895156
   PubMed Web of Science ®Google Scholar
• BurnetMCancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applicationsBr Med J19571502384184713413231
   PubMedGoogle Scholar
• ThomasLOn immunosurveillance in human cancerYale J Biol Med1982553–43293336758376
   PubMed Web of Science ®Google Scholar
• DunnGPBruceATIkedaHOldLJSchreiberRDCancer immunoediting: from immunosurveillance to tumor escapeNat Immunol200231199199812407406
   PubMed Web of Science ®Google Scholar
• DunnGPOldLJSchreiberRDThe immunobiology of cancer immunosurveillance and immunoeditingImmunity200421213714815308095
   PubMed Web of Science ®Google Scholar
• StaggJJohnstoneRWSmythMJFrom cancer immunosurveillance to cancer immunotherapyImmunol Rev200722018210117979841
   PubMed Web of Science ®Google Scholar
• KhongHTRestifoNPNatural selection of tumor variants in the generation of “tumor escape” phenotypesNat Immunol2002311999100512407407
   PubMed Web of Science ®Google Scholar
• ReinkeLFFeemsterLCBackhusLMGylys-ColwellIAuDHAssessment and management of symptoms for outpatients newly diagnosed with lung cancerAm J Hosp Palliat Care201633217818325376224
   PubMedGoogle Scholar
• AntoniaSGettingerSChowLMNivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim Phase I resultsJ Clin Oncol201432Suppl 15 Abstract 8023
   Web of Science ®Google Scholar
• StewartTJAbramsSIHow tumours escape mass destructionOncogene200827455894590318836470
   PubMed Web of Science ®Google Scholar
• PrendergastGCSmithCThomasSIndoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancerCancer Immunol Immunother201463772173524711084
   PubMed Web of Science ®Google Scholar
• VeselyMDKershawMHSchreiberRDSmythMJNatural innate and adaptive immunity to cancerAnnu Rev Immunol20112923527121219185
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol201533171974198225605845
   PubMed Web of Science ®Google Scholar
• DominguesDTurnerASilvaMDImmunotherapy and lung cancer: current developments and novel targeted therapiesImmunotherapy20146111221123525496336
   PubMed Web of Science ®Google Scholar
• Ostrand-RosenbergSHornLAAlvarezJANovel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cellsCancer Immunol Immunother201564101287129325792524
   PubMedGoogle Scholar
• GhoshRKSharmaASharmaNImmune checkpoint inhibitors in advanced nonsmall cell lung cancerCurr Opin Oncol201527210811725602683
   PubMedGoogle Scholar
• PatelSPKurzrockRPD-L1 expression as a predictive biomarker in cancer immunotherapyMol Cancer Ther201514484785625695955
   PubMed Web of Science ®Google Scholar
• DempkeWCMSellmannLFenchelKEdvardsenKImmunotherapies for NSCLC: are we cutting the gordian helix?Anticancer Res201535115745575726503995
   PubMed Web of Science ®Google Scholar
• MayorMYangNStermanDJonesDRAdusumilliPSImmunotherapy for non-small cell lung cancer: current concepts and clinical trialsEur J CardioThoracic Surg201649513241333
   PubMedGoogle Scholar
• AngYLETanH-LSooRABest practice in the treatment of advanced squamous cell lung cancerTher Adv Respir Dis20159522423525902866
   PubMed Web of Science ®Google Scholar
• RizviNAMazièresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol201516325726525704439
   PubMed Web of Science ®Google Scholar
• LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
   PubMed Web of Science ®Google Scholar
• YaqubFNivolumab for squamous-cell non-small-cell lung cancerLancet Oncol2015167e319
   PubMed Web of Science ®Google Scholar
• RoundsAKolesarJNivolumab for second-line treatment of metastatic squamous non-small-cell lung cancerAm J Health Syst Pharm201572211851185526490818
   PubMed Web of Science ®Google Scholar
• MokTSKLoongHHAre we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?Lancet2016387100271488149026712085
   PubMedGoogle Scholar
• GaronEBRizviNAHuiRPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• SwaikaAHammondWAJosephRWCurrent state of anti-PD-L1 and anti-PD-1 agents in cancer therapyMol Immunol201567241725749122
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimD-WPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
   PubMed Web of Science ®Google Scholar
• MonteiroIDCalifanoRMountziosGde MelloRAImmunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigmsFuture Oncol201612455156426776915
   PubMedGoogle Scholar
• GaronEBCurrent perspectives in immunotherapy for non-small cell lung cancerSemin Oncol201542Suppl 2S11S1826477470
   PubMed Web of Science ®Google Scholar
• LeeJSCollardHRImmunotherapy: the third wave in lung cancer treatmentLancet Respir Med201531292392426679022
   PubMedGoogle Scholar
• RizviNChaftJBalmanoukianATumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 statusJ Immunother Cancer20153Suppl 2P193
   Google Scholar
• SocinskiMAIncorporating immunotherapy into the treatment of non-small cell lung cancer: practical guidance for the clinicSemin Oncol201542Suppl 2S19S2826477471
   PubMedGoogle Scholar
• JohnsonDBRiothMJHornLImmune checkpoint inhibitors in NSCLCCurr Treat Options Oncol201415465866925096781
   PubMed Web of Science ®Google Scholar
• ZatloukalPHeoDSParkKRandomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)J Clin Oncol200927Suppl 15 abstr 8071
   Web of Science ®Google Scholar
• VilladolidJAminAImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicitiesTransl Lung Cancer Res20154556057526629425
   PubMed Web of Science ®Google Scholar
• WangJZouZ-HXiaH-LStrengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trialsPLoS One201273e3269522403699
   PubMedGoogle Scholar
• BrownTPilkingtonGBolandAClinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic reviewHealth Technol Assess2013176199
   Google Scholar
• O’MahonySNathanSMohajerRSurvival prediction in ambulatory patients with stage III/IV non-small cell lung cancer using the palliative performance scale, ECOG, and lung cancer symptom scaleAm J Hosp Palliat Care201633437438025670717
   PubMedGoogle Scholar
• de MelloRAPousaIPereiraDNivolumab for advanced squamous cell lung cancer: what are the next steps?Lancet Oncol201516323423525704436
   PubMedGoogle Scholar